Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02266888 · ClinicalTrials.gov registry record · Phase 2
B Cell Induction in Pediatric Lung Transplantation
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02266888 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 45 participants.
The verdict
NCT02266888, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells with rituximab (Rituxan®) can prevent injury to the transplanted lung. This treatment has been studied in other types of solid organ transplants.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Rituximab (Rituxan®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-01-22 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02266888
The ClinicalTrials.gov registry entry for NCT02266888 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02266888 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02266888 about?
NCT02266888 is a clinical study titled "B Cell Induction in Pediatric Lung Transplantation". In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells with rituximab (Rituxan®) can prevent injury to the transplanted lung. This treatment has been studied in other type...
What is the current status of trial NCT02266888?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-01-22. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT02266888?
The interventions under investigation include: Placebo (BIOLOGICAL), Rituximab (Rituxan®) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02266888?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.